Heron Therapeutics/$HRTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Heron Therapeutics

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Ticker

$HRTX
Primary listing

Industry

Biotechnology

Employees

122

ISIN

US4277461020

HRTX Metrics

BasicAdvanced
$305M
-
-$0.06
1.33
-

What the Analysts think about HRTX

Analyst ratings (Buy, Hold, Sell) for Heron Therapeutics stock.

Bulls say / Bears say

Heron Therapeutics achieved a net income of $3.6 million in Q4 2024, marking a significant turnaround from previous losses. (prnewswire.com)
The company's acute care franchise revenue increased by 89.4% in Q1 2025, driven by strong sales of ZYNRELEF and APONVIE. (ir.herontx.com)
Heron secured market exclusivity for CINVANTI and APONVIE until June 1, 2032, following a settlement with Mylan Pharmaceuticals. (ir.herontx.com)
Despite recent profitability, Heron's cash reserves decreased from $59.3 million at the end of 2024 to $50.7 million by March 31, 2025, indicating potential liquidity concerns. (ir.herontx.com)
The company faces challenges in expanding ZYNRELEF's market share, as the transition to the Vial Access Needle (VAN) is still in progress and may impact sales momentum. (ir.herontx.com)
Heron's reliance on partnerships, such as with CrossLink Network, for promotional efforts may lead to increased operational costs and dependency on third-party performance. (ir.herontx.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.

HRTX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

HRTX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HRTX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs